Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In NASH Race, Bad News For Conatus, Good News For Genfit In PBC

Executive Summary

Conatus’ emricasan fails to meet the primary endpoint for portal hypertension in NASH patients with cirrhosis, but firm stresses promising subgroup data. Genfit hits Phase II primary endpoint in PBC with elafibranor, which is also in Phase III for NASH.

You may also be interested in...



Conatus Accepts Defeat For Emricasan In NASH

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

The latest drug development news and highlights from our US FDA Performance Tracker. 

Novartis’s NASH Chief: Our Strategy Is Combos With Tropifexor As ‘Backbone’

Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124318

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel